Are analogue insulins better than soluble in continuous subcutaneous insulin infusion? Results of a meta‐analysis
Authors:
- 26 September 2003
- journal article
- research article
- Published by Wiley in Diabetic Medicine
- Vol. 20 (10) , 863-866
Abstract
Aims The properties of rapid‐acting insulin analogues are thought to be particularly appropriate for use in continuous subcutaneous insulin infusion (CSII) or insulin pump therapy. We conducted a systematic review and meta‐analysis of trials comparing rapid‐acting insulin analogues with soluble insulin in CSII.Methods The following databases were searched (last search June 2002): MEDLINE 1985–2002; Embase 1980–2002; PubMed internet version, records added June 2001 to June 2002; Science Citation Index 1990–2002; BIOSIS 1999–2002; Web of Science Proceedings 1990–2002; and the Cochrane Library, including DARE and the HTA databases. Randomized controlled trials and crossover studies with at least 10 weeks on each treatment were included. Data extraction and quality assessment were undertaken by one reviewer and checked by a second. A meta‐analysis was undertaken using a random effects model.Results A significant improvement of 0.26% (95% confidence interval −0.47, −0.06%) in glycated haemoglobin was demonstrated with lispro. Some studies reported fewer hypoglycaemic episodes with analogue insulin but this varied according to the definitions used. No differences in insulin dosage or weight were seen. Two studies reported patient preference, with analogues preferred in both. The extra cost per annum ranges from £72 (at 40 units per day) to £150 (at 84 units per day).Conclusions Insulin analogues result in a modest but significant reduction in HbA1c compared with soluble insulin when used in CSII, and are preferred by patients.Keywords
This publication has 9 references indexed in Scilit:
- Comparison of Insulin Aspart With Buffered Regular Insulin and Insulin Lispro in Continuous Subcutaneous Insulin InfusionDiabetes Care, 2002
- A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pumpJournal of Diabetes and its Complications, 2001
- Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.Diabetes Care, 1999
- Systematic reviews of published evidence: Miracles or minefields?Annals of Oncology, 1998
- Improvement of HbA1c and Blood Glucose Stability in IDDM Patients Treated With Lispro Insulin Analog in External PumpsDiabetes Care, 1998
- Human insulin analogue [LYS(B28), PRO(B29)]: the ideal pump insulin?Diabetic Medicine, 1998
- Impact on Clinical. Status and Quality of Life of Switching From Regular Insulin to Insulin Lispro Among Patients Using Insulin PumpsThe Diabetes Educator, 1998
- Insulin Lispro: Its Role in the Treatment of Diabetes MellitusAnnals of Pharmacotherapy, 1996
- The Relationship of Glycemic Exposure (HbA1c) to the Risk of Development and Progression of Retinopathy in the Diabetes Control and Complications TrialDiabetes, 1995